Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Bicycle Therapeutics (BCYC) over the last 6 years, with Sep 2025 value amounting to $69.3 million.

  • Bicycle Therapeutics' Shares Outstanding (Diluted Average) rose 0.46% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.3 million, marking a year-over-year increase of 0.46%. This contributed to the annual value of $58.2 million for FY2024, which is 63.54% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Shares Outstanding (Diluted Average) of $69.3 million as of Q3 2025, which was up 0.07% from $69.3 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $69.3 million in Q3 2025 and a low of $22.1 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $52.0 million (2024), whereas its average is $51.4 million.
  • Data for Bicycle Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY spiked of 74.32% (in 2024) over the last 5 years.
  • Over the past 5 years, Bicycle Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $25.1 million in 2021, then increased by 18.35% to $29.7 million in 2022, then climbed by 20.00% to $35.6 million in 2023, then skyrocketed by 63.54% to $58.2 million in 2024, then rose by 0.46% to $69.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $69.3 million in Q3 2025, compared to $69.3 million in Q2 2025 and $69.2 million in Q1 2025.